Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer immunotherapy: The dark side of PD-1 receptor inhibition.

Literature DB >> 29143822

Cancer immunotherapy: The dark side of PD-1 receptor inhibition.

Aya Ludin¹, Leonard I Zon^1,2.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2017 PMID： 29143822 PMCID： PMC6136420 DOI： 10.1038/nature24759

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

× No keyword cloud information.

8 in total

1. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

Authors: Spencer C Wei; Jacob H Levine; Alexandria P Cogdill; Yang Zhao; Nana-Ama A S Anang; Miles C Andrews; Padmanee Sharma; Jing Wang; Jennifer A Wargo; Dana Pe'er; James P Allison
Journal: Cell Date: 2017-08-10 Impact factor: 41.582

Review 2. The emerging role of immune checkpoint inhibition in malignant lymphoma.

Authors: Ida Hude; Stephanie Sasse; Andreas Engert; Paul J Bröckelmann
Journal: Haematologica Date: 2016-11-24 Impact factor: 9.941

Review 3. Serine-threonine kinases in TCR signaling.

Authors: María N Navarro; Doreen A Cantrell
Journal: Nat Immunol Date: 2014-09 Impact factor: 25.606

4. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245

5. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

Authors: Alexander M Lesokhin; Stephen M Ansell; Philippe Armand; Emma C Scott; Ahmad Halwani; Martin Gutierrez; Michael M Millenson; Adam D Cohen; Stephen J Schuster; Daniel Lebovic; Madhav Dhodapkar; David Avigan; Bjoern Chapuy; Azra H Ligon; Gordon J Freeman; Scott J Rodig; Deepika Cattry; Lili Zhu; Joseph F Grosso; M Brigid Bradley Garelik; Margaret A Shipp; Ivan Borrello; John Timmerman
Journal: J Clin Oncol Date: 2016-06-06 Impact factor: 44.544

6. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors: Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; John Wagstaff; Dirk Schadendorf; Pier F Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A Ascierto; Georgina V Long; Jonathan Cebon; Jeffrey Sosman; Michael A Postow; Margaret K Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F Stephen Hodi; James Larkin
Journal: N Engl J Med Date: 2017-09-11 Impact factor: 91.245

7. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.

Authors: Tim Wartewig; Zsuzsanna Kurgyis; Selina Keppler; Konstanze Pechloff; Erik Hameister; Rupert Öllinger; Roman Maresch; Thorsten Buch; Katja Steiger; Christof Winter; Roland Rad; Jürgen Ruland
Journal: Nature Date: 2017-11-15 Impact factor: 49.962

8. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

Authors: Sydney R Gordon; Roy L Maute; Ben W Dulken; Gregor Hutter; Benson M George; Melissa N McCracken; Rohit Gupta; Jonathan M Tsai; Rahul Sinha; Daniel Corey; Aaron M Ring; Andrew J Connolly; Irving L Weissman
Journal: Nature Date: 2017-05-17 Impact factor: 49.962

8 in total

15 in total

Review 1. Recent advances in sonodynamic immunotherapy.

Authors: Hui Wang; Guo-Qing Sui; Zhi-Xia Sun; Jia-Rui Du; Yang Wang; Zong-Hua Yue; Han-Yu Zhang
Journal: J Cancer Res Clin Oncol Date: 2022-07-13 Impact factor: 4.322

2. Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer.

Authors: Qing Zhao; Xuexin He; Xiyi Qin; Yu Liu; Han Jiang; Jing Wang; Shuang Wu; Rui Zhou; Congcong Yu; Suling Liu; Hong Zhang; Mei Tian
Journal: Front Immunol Date: 2022-06-23 Impact factor: 8.786

3. Hybrid phenotype mining method for investigating off-target protein and underlying side effects of anti-tumor immunotherapy.

Authors: Yuyu Zheng; Xiangyu Meng; Pierre Zweigenbaum; Lingling Chen; Jingbo Xia
Journal: BMC Med Inform Decis Mak Date: 2020-07-09 Impact factor: 2.796

Review 4. Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers.

Authors: Bo Yang; Tingjun Liu; Yang Qu; Hangbo Liu; Song Guo Zheng; Bin Cheng; Jianbo Sun
Journal: Front Oncol Date: 2018-11-28 Impact factor: 6.244

Review 5. Immuno-Oncology: Emerging Targets and Combination Therapies.

Authors: Henry T Marshall; Mustafa B A Djamgoz
Journal: Front Oncol Date: 2018-08-23 Impact factor: 6.244

6. Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice.

Authors: Wenwen Yue; Liang Chen; Luodan Yu; Bangguo Zhou; Haohao Yin; Weiwei Ren; Chang Liu; Lehang Guo; Yifeng Zhang; Liping Sun; Kun Zhang; Huixiong Xu; Yu Chen
Journal: Nat Commun Date: 2019-05-02 Impact factor: 14.919